Puma BiotechnologyPBYI
About: Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Employees: 172
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
756% more call options, than puts
Call options by funds: $137K | Put options by funds: $16K
147% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 19
80% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 15
17% more capital invested
Capital invested by funds: $75.9M [Q3] → $89.1M (+$13.2M) [Q4]
10% more funds holding
Funds holding: 100 [Q3] → 110 (+10) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
4.17% less ownership
Funds ownership: 60.63% [Q3] → 56.47% (-4.17%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Edward White 22% 1-year accuracy 32 / 148 met price target | 120%upside $7 | Buy Reiterated | 28 Feb 2025 |
Financial journalist opinion
Based on 8 articles about PBYI published over the past 30 days
